ArticleAnnals of surgical oncology2026
Intraoperative Radiotherapy for Breast Cancer: Long-Term Experience.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTargeted intraoperative radiation therapy (TARGIT-IORT) is a promising alternative to standard external radiation for the treatment of early-stage breast cancer. However, American Society for Radiation Oncology guidelines have limited its use. We aimed to present our long-term results with the use of TARGIT-IORT in a very restricted population.
methodsThe electronic records of a tertiary medical center were retrospectively searched for women diagnosed with invasive ductal carcinoma from 2014 to 2023. Inclusion criteria were age > 50 years, unifocal disease, tumor size < 3 cm, and clinical subtype estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-non-amplified. Those with a favorable pathology after completion of lumpectomy and sentinel lymph node biopsy (SLNB) underwent TARGIT-IORT consisting of delivery of a single high dose of radiation (20 Gy) to an applicator inserted into the tumor bed using low-energy X-rays (50 Kv) over 22-29 minutes. Follow-up consisted of clinical examination every 6 months in the first 2 years and then mammography and breast ultrasound annually.
resultsThe cohort included 219 patients with a median age of 66 years (range 50-83). During a median follow-up of 85 months, there was one case each (0.45%) of ipsilateral breast tumor recurrence, axillary lymph node recurrence, and isolated liver metastasis. In total, 20 patients (9.1%) had minor wound complications, and three (1.4%) had fat necrosis, self-limiting in all cases, with no need for hospital readmission.
conclusionTARGIT-IORT is associated with excellent local control, very high survival rates, and a very low toxicity profile for low-risk early breast cancer, consistent with the TARGIT-A trial and should be offered to patients when suitable.
Indexed as
Identifiers
42371320What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.